Effect of prophylactic treatment with levetiracetam on the incidence of postattenuation seizures in dogs undergoing surgical management of single congenital extrahepatic portosystemic shunts by Mullins, Ronan A et al.

OR I G I NA L ART I C L E – CL I N I C AL
Effect of prophylactic treatment with levetiracetam
on the incidence of postattenuation seizures in dogs
undergoing surgical management of single congenital
extrahepatic portosystemic shunts
Ronan A. Mullins MVB1 | Carlos Sanchez Villamil DVM1 |
Hilde de Rooster DVM, MVM, PhD, DECVS2 | Anne Kummeling DVM, PhD, DECVS3 |
Robert N. White BSc(Hons), BVetMed, DSAS(ST), DECVS, SFHEA4,5,6 |
Kelley M. Thieman Mankin DVM, MS, DACVS-SA7 |
Michael S. Tivers BVSc(Hons), PhD, DECVS8 | Donald A. Yool BVMS, PhD, DECVS, SFHEA9 |
Davina M. Anderson MA VetMB, PhD, DSAS(ST), DECVS10 |
Kathryn M. Pratschke MVB, MVM, DECVS11,12 | Ines Gordo DVM, MS13 |
Herve Brissot DEDV, DECVS13 | Ameet Singh BSc, DVM, DVSc, DACVS14 |
Melanie Olive DVM15 | Jean Phillipe Billet Dr.vét, Cert SAS, DECVS15 |
Laura E. Selmic BVetMed (Hons), MPH, DACVS-SA, DECVS16 |
Barbara M. Kirby DVM, MS, DACVS, DECVS1
1Section of Veterinary Clinical Sciences, University
College Dublin, Belfield, Dublin, Ireland
2Small Animal Department, Faculty of Veterinary
Medicine, Ghent University, Merelbeke, Belgium
3Department of Clinical Sciences of Companion
Animals, Faculty of Veterinary Medicine, Utrecht
University, Utrecht, The Netherlands
4Willows Veterinary Centre and Referral Service,
Shirley, Solihull, West Midlands, United Kingdom
5Abbey House Veterinary Hospital, Morley,
Leeds, United Kingdom
6School of Veterinary Medicine & Science,
University of Nottingham, Sutton Bonington
Campus, Loughborough, United Kingdom
7Department of Small Animal Clinical Sciences,
College of Veterinary Medicine and Biomedical
Sciences, Texas A&M University, College Station,
Texas
Abstract
Objective: To report the incidence of postattenuation seizures (PAS) in dogs that
underwent single congenital extrahepatic portosystemic shunt (cEHPSS) attenua-
tion and to compare incidence of PAS in dogs that either did or did not receive pro-
phylactic treatment with levetiracetam (LEV).
Study design:Multi-institutional retrospective study.
Population: Nine hundred forty dogs.
Methods: Medical records were reviewed to identify dogs that underwent surgical
attenuation of a single cEHPSS from January 2005 through July 2017 and devel-
oped PAS within 7 days postoperatively. Dogs were divided into 3 groups: no
LEV (LEV−); LEV at ≥15 mg/kg every 8 hours for ≥24 hours preoperatively or a
60 mg/kg intravenous loading dose perioperatively, followed by ≥15 mg/kg every
8 hours postoperatively (LEV1); and LEV at <15 mg/kg every 8 hours, for
<24 hours preoperatively, or continued at <15 mg/kg every 8 hours postopera-
tively (LEV2).
Preliminary results of this study were presented at the Association of Veteri-
nary Soft Tissue Surgeons' Annual Spring Meeting; April 4, 2018; Birming-
ham, United Kingdom; and the ACVS Surgery Summit, October 25–27,
2018; Phoenix, Arizona. This study represents part of a thesis submitted by
Dr. Mullins to the University College Dublin in partial fulfillment of a Doc-
torate of Veterinary Medical Specialization.
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Results: Seventy-five (8.0%) dogs developed PAS. Incidence of PAS was 35 of
523 (6.7%), 21 of 188 (11.2%), and 19 of 228 (8.3%) in groups LEV-, LEV1, and
LEV2, respectively. This difference was not statistically significant (P = .14). No
differences between groups of dogs that seized with respect to investigated vari-
ables were identified.
Conclusion: The overall incidence of PAS was low (8%). Prophylactic treatment
with LEV according to the protocols that were investigated in our study was not
associated with a reduced incidence of PAS.
Clinical significance: Prophylactic treatment with LEV does not afford protection
against development of PAS. Surgically treated dogs should continue to be moni-
tored closely during the first 7 days postoperatively for seizures.
1 | INTRODUCTION
Development of postattenuation seizures (PAS) is a devastat-
ing and frequently fatal postoperative complication in dogs
undergoing surgical attenuation of congenital portosystemic
shunts, with survival rates ranging from 0%-53.8% in previous
studies that included more than 3 affected dogs.1–7 Incidence
of PAS has been reported as high as 18.2%1,2,4–8 and up to
4.7%-8.1% in more recent literature.6,7 Seizures typically
occur within 96 hours postoperatively and have been
reported after congenital extrahepatic portosystemic shunt
(cEHPSS)1–18 and, less commonly, intrahepatic portosystemic
shunt (cIHPSS) attenuation.13,14,19–25 Such seizures appear
different from those observed preoperatively in that they are
often very challenging to control, often being refractory to
typical first-line antiseizure medications.1–8,10–12,14–16,21,22
The etiopathogenesis of PAS remains unknown. The most
commonly cited cause is a decrease in systemic concentrations
of endogenous benzodiazepines/benzodiazepine-like substances
from the portal circulation after shunt attenuation.26 Other sug-
gested causes include hypoglycemia, hepatic encephalopathy,
hypoxemia/hypoxic brain injury, systemic hypertension, elec-
trolyte disturbances, and concurrent brain disease.2,3,17,18,21
None of these, however, have been consistently identified in
affected dogs.1–3,6–11,15,17,18,21,22 Prolonged surgical and anes-
thetic times and intraoperative hypotension have anecdotally
been suggested to be implicated in PAS; however, these are not
supported by results from a recent study.6
Risk factors for development of PAS are not well
established.7 Development of seizures has not been pre-
vented by partial ligation,1–3,9,12,20,21 use of delayed attenua-
tion devices,3–5,10,12,14,15,17,22,23 or coil embolization.24,25 In
a recent study, increasing age and the presence of hepatic
encephalopathy (HE) immediately preoperatively were
identified as risk factors for development of postattenuation
neurologic signs (PANS) and PAS.7 Matushek et al1 reported
that 40% of dogs that developed PAS had a history of preop-
erative HE. In a study by Tisdall et al,3 dogs with cEHPSS
were significantly more likely to develop PANS compared
with dogs with cIHPSS; however, this is not supported by
2 more recent studies.7,14 In the study by Tisdall et al,3 there
was also a trend toward dogs with portoazygous shunts being
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at greater risk of PANS compared with those with other
shunt morphologies. Certain breeds have been suggested to
be at increased risk of PANS/PAS, including pugs,3,10,17
Jack Russell terriers,14 and Maltese terriers.9
Efforts to reduce the incidence of PAS in dogs undergoing
cEHPSS attenuation have included pretreatment with
phenobarbital,3,10,15 potassium bromide,4,23 and levetiracetam
(LEV).5–7 In one study,3 no dog that received prophylactic phe-
nobarbital experienced postoperative generalized seizures; how-
ever, the overall incidence of PANS was not significantly
decreased. Development of seizures has also been described
after pretreatment with potassium bromide.4,23 There are con-
flicting reports in the literature regarding the possible protective
effects of LEV against development of PAS.5–7 Findings of a
retrospective study by Fryer et al in 2011 led to a paradigm
shift in the preoperative management of dogs undergoing shunt
attenuation in many institutions. In that study, no dog that
received LEV at a dose of 20 mg/kg every 8 hours for a mini-
mum of 24 hours preoperatively experienced PAS. Conversely,
5% of dogs that did not receive LEV pretreatment experienced
PAS, leading to a decision for humane euthanasia.5 These
results, however, are not supported by 2 more recent studies6,7
in which pretreatment with LEV was not associated with
reduced incidence of PAS. Therefore, the objectives of our
study were (1) to report the incidence of PAS in a large cohort
of dogs that underwent cEHPSS attenuation and (2) to compare
incidence of PAS in dogs that either did or did not receive pro-
phylactic LEV. Our hypothesis was that there would be no sig-
nificant difference in incidence of PAS among dogs that either
did or did not receive prophylactic LEV.
2 | MATERIALS AND METHODS
2.1 | Inclusion and exclusion criteria
Medical records at 10 veterinary institutions were retrospec-
tively reviewed to identify dogs that underwent surgical attenu-
ation (suture ligation [SL], thin film banding [TFB], or
ameroid ring constrictor [ARC] placement) of a single
cEHPSS from January 2005 through July 2017. In addition,
2 of the authors (RNW, KMP) performed surgery at more than
1 institution during the study period. All cEHPSS operated by
these 2 surgeons during this time frame were reviewed, and
incidence of PAS was calculated on an individual rather than
institutional basis. Exclusion criteria included cIHPSS; multi-
ple cEHPSS; cEHPSS with apparent portal vein aplasia that
precluded shunt attenuation; pretreatment with antiseizure
medication(s) other than LEV within 1 month prior to surgery;
dogs that died or were euthanized within 24 hours postopera-
tively for reasons unrelated to seizure activity; dogs that
received LEV preoperatively but did not have it continued
postoperatively, dogs that received LEV postoperatively only;
and dogs with incomplete medical records to permit stratifica-
tion into the appropriate group. Institutions that biased
administration of LEV toward dogs perceived to be at greater
risk of PAS were not included in this study. Postattenuation
seizures were defined as those that occurred within 7 days
postoperatively. Dogs that experienced onset of seizure activity
after 7 days were recorded as not having developed PAS.
2.2 | Data collection
2.2.1 | All dogs
Each contributing institution/surgeon assigned all dogs that
satisfied the inclusion criteria to 1 of 3 groups:
1. Group LEV−: Dogs that received no antiseizure
prophylaxis
2. Group LEV1: Dogs that received LEV at a dose of
≥15 mg/kg every 8 hours for ≥24 hours preoperatively
or a 60 mg/kg intravenous loading dose of LEV peri-
operatively, with continuation of LEV postoperatively at
a dose of ≥15 mg/kg every 8 hours
3. Group LEV2: Dogs that received LEV at a dose of
<15 mg/kg every 8 hours, for <24 hours preoperatively,
or continued at <15 mg/kg every 8 hours postoperatively
Dogs that received less than every 8 hours administration
of LEV (regardless of accompanying dose) were assigned to
group LEV2. Postoperative duration of LEV was also
recorded for all dogs in groups LEV1 and LEV2.
2.2.2 | Dogs that developed PAS
Additional data retrieved only from the medical record of
dogs that developed PAS within 7 days postoperatively and
compared between groups of affected dogs included breed,
age, sex/neuter status, and body weight at time of surgery;
shunt morphology (portocaval, portoazygous, or portophre-
nic); concurrent/historical conditions at presentation;
presence of preoperative neurologic signs; presence of preop-
erative seizures; method of shunt identification (abdominal
ultrasound, computed tomography angiography [CTA], scin-
tigraphy, intraoperative portovenography [IOPV], MRI);
details of preoperative medical management (diet, antimicro-
bial, lactulose); method of shunt attenuation (SL, TFB, ARC)
and degree of acute intraoperative attenuation (none, partial,
or complete); type and timing of PAS; and electrolyte
(sodium, potassium, and chloride), glucose, and ammonia
concentrations about the time of PAS occurrence (when
available). Dogs that received preoperative antimicrobial and
lactulose medication were recorded as either having received
these medications for a minimum of 1 week prior to surgery
or not. For dogs that received prophylactic LEV, timing of
the last preoperative dose in relation to commencement of
surgery and the most recently administered dose relative to
seizure onset (in hours) were recorded. Timing of occurrence
of seizures was recorded in hours when available or con-
verted to hours if recorded in days. Dogs were stratified as
having experienced partial/focal seizures only or as having
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experienced generalized seizures with or without partial/focal
seizures. For dogs that developed PAS, short-term survival,
defined as survival to 30 days, was also recorded.
2.3 | Statistical analysis
Continuous variables were tested for normality by using the
Shapiro-Wilk test. Normally distributed continuous data are
presented as mean and standard deviation. Nonnormally
distributed continuous data are presented as median and range.
Categorical variables are presented as frequency and percent-
ages (with 95% CI). Normally distributed continuous data were
compared among groups of dogs that experienced PAS by
using 1-way ANOVA. Nonnormally distributed continuous
data were compared by using the Kruskal-Wallis and Mann-
Whitney U tests, whereas categorical variables were compared
among PAS groups by using Pearson's χ2 test. A power analy-
sis based on a modification of previously published data5 was
performed. In that study,5 dogs that did and did not receive
pretreatment with LEV had a 0% and 5% incidence of PAS,
respectively. With an incidence of 1% and 5%, respectively, a
total of 284 dogs per group would be required to show a true
difference between 2 groups if a difference were to exist, with
a power of 80% and an α of .05. P < .05 was considered sig-
nificant. Statistical analyses were performed in SPSS Statistics
version 24 (IBM, Armonk, New York).
3 | RESULTS
In total, 940 dogs satisfied the inclusion criteria and
were included in the study. Among these, 75 (8.0%; CI:
6.4%-9.9%) dogs developed PAS. Details of 3 dogs were par-
tially reported previously.15,16 Incidence of PAS within
individual institutions is listed in Table 1.
3.1 | Group LEV−
Five hundred twenty-three dogs were included in group
LEV−; 35 (6.7%; CI: 4.9-9.2%) dogs developed PAS.
3.2 | Group LEV1
One hundred eighty-eight dogs were included in group
LEV1; 21 (11.2%; CI: 7.4%-16.5%) dogs developed PAS. All
21 dogs were still receiving LEV at the time of PAS occur-
rence. Median postoperative duration of LEV of 167 dogs in
group LEV1 that did not develop PAS was 10 days (range,
1-760), recorded as indefinitely (n = 1), not recorded
(n = 2). Among those that developed PAS (n = 21), duration
of pretreatment (excluding 2 dogs that received a 60 mg/kg
intravenous loading dose perioperatively) was 6 days (range,
1-237); preoperative dose was 20 mg/kg (range, 15-60 mg/kg
[76.2% of dogs received ≥20 mg/kg]); all received every
8 hours administration of LEV preoperatively and postopera-
tively (excluding 2 dogs that received a 60 mg/kg intravenous
loading dose perioperatively); and median postoperative dose
was 20 mg/kg every 8 hours (range, 15-23 mg/kg [85.7% of
dogs received ≥20 mg/kg]).
3.3 | Group LEV2
Two hundred twenty-nine dogs were included in group
LEV2; 19 (8.3%; CI: 5.4%-12.6%) dogs developed PAS. All
19 dogs were still receiving LEV at the time of PAS occur-
rence. Median postoperative duration of LEV administration
of 209 dogs in group LEV2 that did not develop PAS was
7 days (range, 2-66); not recorded (n = 3). Among those that
developed PAS (n = 19), median duration of pretreatment
was 72 hours (range, 12.7 hours to 97 days), with 2 additional
dogs recorded as having commenced LEV pretreatment peri-
operatively (n = 1; 20 mg/kg and continued at 20 mg/kg
every 8 hours postoperatively) or intraoperatively (n = 1;
60 mg/kg loading dose but continued at 19.23 mg/kg every
12 hours postoperatively); median preoperative dose was
20 mg/kg (range, 10-20 mg/kg); 10 dogs received every 8
hours administration preoperatively, and 6 dogs received
every 12 hours administration, whereas 3 dogs received a
single dose preoperatively (2 dogs perioperatively/intrao-
peratively and 1 dog 12.6 hours preoperatively); median
postoperative dose was 20 mg/kg (range, 10-20 mg/kg);
13 dogs received every 8 hours administration postopera-
tively, whereas the remaining 6 dogs received every 12 hours
administration.
The incidence of PAS did not differ between groups
(P = .14). No significant differences between groups of
TABLE 1 Incidence of postattenuation seizures among 940 dogs that
underwent single cEHPSS attenuation
Group
Institution LEV− LEV1 LEV2
1, n (%) 2/114 (1.8) … 3/41 (7.3)
2, n (%)a 5/59 (8.5) 3/18 (16.7) 0/24 (0.0)
3, n (%) 1/17 (5.9) 1/18 (5.6) 1/12 (8.3)
4, n (%) 6/161 (3.7) … …
5, n (%) 1/19 (5.3) 2/31 (6.5) 1/17 (5.9)
6, n (%) 4/40 (10.0) 2/14 (14.3) 2/7 (28.6)
7, n (%) 1/6 (16.7) 1/10 (10.0) …
8, n (%) … 4/24 (16.7) 5/20 (25.0)
9, n (%) 0/12 (0.0) 5/59 (8.5) 0/25 (0.0)
10, n (%) 4/34 (11.8) 3/7 (42.9) 5/43 (11.6)
11, n (%) 5/32 (15.6) 0/7 (0.0) 1/11 (9.1)
12, n (%)a 6/30 (20.0) … 1/28 (3.6)
Total dogs, n 524 188 228
Dogs that developed
PAS, n
35 21 19
Incidence of PAS,
% (95% CI)
6.7 (4.9-9.2) 11.2 (7.4-16.5) 8.3 (5.4-12.6)
…, no data; LEV, levetiracetam; PAS, postattenuation seizures.
a cEHPSS by an individual surgeon rather than an institution.
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TABLE 2 Comparison of variables among groups of dogs that developed PAS
Group
Variable LEV− LEV1 LEV2 P-value
Breed (n) Mixed breed (7) Mixed breed (4) Mixed breed (5) .06
Bichon frise (7) Yorkshire terrier (3) Bichon frise (3)
Yorkshire terrier (6) Shih tzu (3) Jack Russell terrier (3)
Shih tzu (5) Chihuahua (3) Pug (2)
Maltese terrier (4) Pug (2) Dachshund (2)
Pug (4) Maltese terrier (1) Maltese terrier (1)
Miniature schnauzer (1) Miniature schnauzer (1) West Highland white terrier (1)
Jack Russell terrier (1) Jack Russell terrier (1) Brussels griffon (1)
Dachshund (1) Setter (1)
Norfolk terrier (1)
Border terrier (1)
Age, median (range), mo 35 (4-115) 34 (6-59) 35 (8-105) .68
Sex/neuter status (n) Male intact (7) Male intact (5) Male intact (1) .34
Male neutered (13) Male neutered (4) Male neutered (8)
Female intact (6) Female intact (3) Female intact (4)
Female spayed (7) Female spayed (9) Female spayed (6)
Unspecified female (2)
Weight, median (range), kg 6.8 (2.2-11.9) 6.0 (2.0-13.6) 6.5 (4.2-21.0) .46
Shunt morphology (n) Portocaval (26) Portocaval (14) Portocaval (13) .97
Portoazygous (5) Portoazygous (4) Portoazygous (4)
Portophrenic (3) Portophrenic (2) Portophrenic (2)
Presence of concurrent/historical conditions at
presentation, n (%)
9/35 (25.7) 10/21 (47.6) 6/19 (31.6) .24
Presence of preoperative neurologic signs, n
(%)
29/35 (82.9) 16/21 (76.2) 16/19 (84.2) .77
Presence of preoperative seizures, n (%) 4/35 (11.4) 5/21 (23.8) 2/19 (10.5) .38
Preoperative diet (n) Hepatic diet (23) Hepatic diet (14) Hepatic diet (11) .47
Unspecified protein-restricted diet
(3)
Unspecified protein-restricted
diet (4)
Hypoallergenic diet (2)
Protein-restricted renal diet (1) Hypoallergenic diet (1) Unspecified protein-restricted
diet (1)
Other diet (2) Vegetarian diet (1) Gastrointestinal diet (1)
Vegetarian diet (1)
Minimum of 7 days of preoperative
antimicrobial(s), n (%)
33/35 (94.3) 19/21 (90.5) 14/18 (77.8) .18
Minimum of 7 days of preoperative lactulose,
n (%)
34/35 (97.1) 19/21 (90.5) 15/18 (83.3) .21
(i) Method and (ii) degree of SL (13) TFB (9) TFB (10) (i) .45
acute intraoperative shunt Complete ligation (11) No attenuation (5) No attenuation (6) (ii) .27
attenuation (n) Partial ligation (2) Partial attenuation (4) Partial attenuation (4)
TFB (11) ARC (8) SL (6)
No attenuation (1) No attenuation (8) Complete ligation (5)
Partial attenuation (10) Partial ligation (1)
ARC (10) SL (4) ARC (3)
No attenuation (10) Complete ligation (4) No attenuation (3)
Combination of SL and TFB (1)
Partial attenuation (1)
Type of postattenuation 28/35 (80) generalized PAS 17/21 (81) generalized PAS 17/19 (89.5) generalized PAS .66
seizures, n (%) 7/35 (20) focal PAS only 4/21 (19) focal PAS only 2/19 (10.5) focal PAS only
Onset of seizure activity median (range), h 60 (8-120) 60 (17-128) 47 (20-120) .06
Sodium, n = 31, median (range), mmol/L 143.0 (135.1-171) 148.0 (142.5-155) 144.0 (138.3-150.3) .24
Potassium, n = 31, mean (SD), mmol/L 4.1 (±0.6) 3.7 (±0.6) 4.1 (±0.3) 0.37
(Continues)
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dogs that seized with respect to variables investigated were
identified (Table 2).
3.4 | Demographics of dogs that developed PAS
The most common breeds were mixed breed (n = 16),
bichon frise (n = 10), Yorkshire terrier (n = 9), shih tzu
(n = 8), and pug (n = 8). Median age was 34 months
(range, 4-115). There were 25 neutered males, 22 spayed
females, 13 intact males, 13 intact females, and 2 unspecified
females. Median weight was 6.2 kg (range, 2.0-21.0).
3.5 | Method of shunt identification and shunt
morphology of dogs that developed PAS
Method of shunt identification included abdominal ultrasound
(n = 61; 81.3%), CTA (n = 21; 28.0%), IOPV (n = 17;
22.7%), scintigraphy (n = 1; 1.3%), and MRI (n = 1; 1.3%).
Information regarding shunt morphology was available for
73 of 75 (97.3%) dogs. Overall, shunt types included portocaval
(n = 53), portoazygous (n = 13), and portophrenic (n = 7).
3.6 | Concurrent/historical conditions at presentation
in dogs that developed PAS
Concurrent/historical conditions were recorded in 25 of
75 (33.3%) dogs and most commonly included urolithiasis
(n = 17), urinary tract infection (n = 6), and cardiac mur-
mur (n = 3). Two dogs had previously undergone cEHPSS
attenuation but did not develop PAS after initial surgery.
3.7 | Incidence of preoperative neurologic signs and
seizures in dogs that developed PAS
Preoperative neurologic signs were recorded in 61 of
75 (81.3%) dogs and most commonly included lethargy
(n = 28), pacing/compulsive walking (n = 12), dullness
(n = 10), head pressing (n = 10), ataxia (n = 10), abnor-
mal/change in behavior (n = 10), hypersalivation/drooling
(n = 9), circling (n = 5), (possible) blindness (n = 4), dis-
orientation (n = 4), sleepy/inappropriate sleeping/sleeps a
lot (n = 4), depression (n = 4), and 2 each of twitching,
weakness, and restlessness. Preoperative seizures were
recorded in 11 of 75 (14.7%) dogs.
3.8 | Details of preoperative medical management of
dogs that developed PAS
Information regarding preoperative medical management
was available for 74 of 75 (98.7%) dogs. One dog (group
LEV2) was prescribed a hepatic diet, an antimicrobial, and
lactulose, but it could not be confirmed if this occurred.
Overall, 48 of 75 (64.0%) dogs received a prescription
hepatic diet; 8 (10.7%) dogs received an unspecified protein-
restricted diet; 3 (4.0%) dogs received a prescription
hypoallergenic diet; 2 (2.7%) dogs received an unspecified
vegetarian diet; and 4 dogs received 1 each of protein-
restricted renal diet, prescription gastrointestinal diet,
homemade protein-restricted diet, and chicken and vegeta-
bles. Sixty-six (88.0%) dogs received a minimum of 7 days
of preoperative antimicrobial, whereas 68 (90.7%) dogs
received a minimum of 7 days of preoperative lactulose.
3.9 | Method and degree of acute intraoperative shunt
attenuation in dogs that developed PAS
Shunts were attenuated by using TFB (n = 30; 40.0%), SL
(n = 23; 30.7%), ARC (n = 21; 28.0%), or a combination of
SL and TFB (n = 1; 1.3%).
3.10 | Type and timing of PAS
Sixty-two (82.7%) dogs experienced generalized PAS,
whereas the remaining 13 (17.3%) dogs experienced focal
PAS only. Onset of seizure activity (focal or generalized,
whichever occurred first) occurred after a median of 48 hours
(range, 8-128) postoperatively.
3.11 | Clinicopathologic variables at time of seizures
(Table 2)
3.11.1 | Sodium, potassium, and chloride
Sodium and potassium concentrations at the time of seizures
were available for review in 31 of 75 (41.3%) dogs and
TABLE 2 (Continued)
Group
Variable LEV− LEV1 LEV2 P-value
Chloride, n = 22, mean (SD), mmol/L 114.6 (±6.7) 112.5 (±5.8) 117.4 (±7.5) .49
Ammonia, n = 30, median (range), μmol/L 39 (8.0-72.6) 37.1 (0.0-104) 25 (2.0-261.6) .84
Glucose, n = 36, median (range), mmol/L 4.9 (2.4-7.2) 5.3 (3.6-6.4) 5.5 (1.1-6.3) .56
Timing of last preoperative dose of LEV in
relation to surgery (n = 16), median
(range), min
… 240 (80-480) 180 (95-750); > 480 min
(750 min; n = 1)
.54
Timing of last (most recent) dose of LEV
relative to seizure onset, n = 16, mean
(SD) min
… 383.8 (±52.7) 278.2 (±162.5); > 480 min
(530 min; n = 1)
.07
Short-term survival, n (%) 14/35 (40) 6/19 (31.6) 3/19 (15.8) .19
…, no data; ARC; ameroid ring constrictor, LEV, levetiracetam; PAS; postattenuation seizures, SL; suture ligation, TFB; thin film banding.
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recorded as normal in a further 3 dogs. Sodium and potas-
sium concentrations were available for 14 of 35 (40%), 5 of
21 (23.8%), and 12 of 19 (63.2%) dogs in groups LEV−,
LEV1, and LEV2, respectively. Chloride concentration was
available for review in 22 of 75 (29.3%) PAS dogs, recorded
as normal in 2 dogs and high in a further 1 dog. Chloride
concentration was available for 10 of 35 (28.6%), 4 of
21 (19.0%), and 8 of 19 (42.1%) dogs in groups LEV−,
LEV1, and LEV2, respectively.
3.11.2 | Ammonia and glucose
Ammonia concentration was available for review in 30 of
75 (40.0%) dogs, recorded as within normal limits for
4 (5.3%) and high for 1 further dog (1.3%). Overall, 76.7%
of values were <70.0 μmol/L. Ammonia concentration was
available for 9 of 35 (25.7%), 10 of 21 (47.6%), and 11 of
19 (57.9%) dogs in groups LEV−, LEV1, and LEV2, respec-
tively. Glucose concentration was available for 36 of
75 (48.0%) dogs and recorded as normal for a further 2 dogs.
Overall, 34 of 37 (91.9%) values were ≥3.3 mmol/L. Glu-
cose concentration was available for 14 of 35 (40%), 7 of
21 (33.3%), and 15 of 19 (78.9%) dogs in groups LEV−,
LEV1, and LEV2, respectively.
3.12 | Timing of last preoperative dose of LEV in
relation to surgery
Timing of the last preoperative dose of LEV in relation to
surgery was available for 9 of 21 (42.9%) dogs in group
LEV1 and 7 of 19 (36.8%) dogs in group LEV2. In addition,
timing of last preoperative dose was recorded as periopera-
tive in 7 of 21 (33.3%) dogs in group LEV1 and 6 of
19 (31.6%) dogs in group LEV2. One additional dog in
group LEV2 received the last preoperative dose of LEV the
previous day.
3.13 | Timing of last (most recent) dose of LEV relative
to seizure onset
Timing of the last dose of LEV in relation to seizure onset
was available for 16 of 40 (40.0%) dogs; 5 (23.8%) dogs in
group LEV1 and 11 (57.9%) dogs in group LEV2 (Table 2).
3.14 | Short-term survival of dogs that developed PAS
Overall, 23 of 75 (30.7%) dogs survived to 30 days
postoperatively.
4 | DISCUSSION
The main findings of this study are (1) that the overall inci-
dence of PAS was low (8%) and similar to that reported in
recent literature6,7 and (2) that prophylactic treatment with
LEV, at either ≥15 mg/kg every 8 hours for ≥24 hours pre-
operatively or a 60 mg/kg intravenous loading dose
perioperatively with continuation postoperatively at ≥15 mg/kg
every 8 hours (group LEV1) or other less standardized LEV
protocols (LEV2), did not result in a reduced incidence of
PAS compared with dogs that did not receive any prophylac-
tic LEV (group LEV−). No significant differences were
identified between groups of dogs that seized with respect to
signalment; shunt morphology; concurrent conditions; inci-
dence of preoperative neurologic signs and seizures; preop-
erative medical management; method and degree of shunt
attenuation; type and timing of PAS; electrolyte, ammonia
and glucose concentrations at the time of seizures; and short-
term survival. The results of this study provide evidence to
corroborate findings of 2 recent studies6,7 that prophylactic
treatment with LEV does not afford protection against devel-
opment of PAS in contrast to what has been suggested by
Fryer et al.5
In a pharmacokinetic study by Moore et al,27 administra-
tion of LEV at 20 mg/kg every 8 hours consistently pro-
duced plasma LEV concentrations within the 5-45 μg/ml
therapeutic range in healthy dogs. This therapeutic range is
based on extrapolations from humans; the plasma LEV con-
centrations required to prevent seizures in dogs undergoing
cEHPSS attenuation is unknown. In our study, we included
dogs that received LEV at ≥15 mg/kg every 8 hours in
group LEV1 to accommodate for expected small deviations
from the recommended 20 mg/kg dose because of tablet size
limitations. The median preoperative dose of LEV in dogs
that developed PAS in group LEV1 was 20 mg/kg, with
over 75% of dogs receiving ≥20 mg/kg every 8 hours preop-
eratively and postoperatively. In the study by Moore et al,27
mean terminal half-life of LEV was 3.6 hours, which
resulted in steady state after 18 hours (K. Muñana, personal
communication, March 2018). These pharmacokinetic data
provide evidence to support that steady-state should have
been achieved at the time of surgery in dogs in group LEV1
in our study. Furthermore, these data provide evidence to
suggest that there is no benefit in pretreating dogs for
>24 hours prior to surgery. We also included in group
LEV1 dogs that received a 60 mg/kg intravenous loading
dose of LEV perioperatively. According to a pharmacoki-
netic study,28 administration of a single intravenous
60 mg/kg loading dose resulted in plasma LEV concentra-
tions within or above the recommended therapeutic range for
at least 8 hours. This was followed with postoperative
administration of LEV at a dose of ≥15 mg/kg every 8 hours
in such dogs in group LEV1 in our study. We did not include
in our study dogs that received other antiseizure medication
concurrently with LEV because of expected alterations in the
pharmacokinetics of LEV.29,30
The median age (34 months) of dogs that developed PAS
in our study was greater than the expected age of dogs under-
going cEHPSS attenuation.31 This observation that older dogs
may be at increased risk of experiencing PANS/PAS has been
made by several other investigators.1–4,7,17 In a recent study
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by Strickland et al,7 increasing age was found to be a signifi-
cant risk factor for development of PANS and PAS.
Postoperative administration of LEV in our study was
very variable, reflecting its multicenter nature, with similar
variation reported in the literature.5–7 In a recent study by
Strickland et al,7 all dogs that were administered LEV
received the drug for a minimum of 5 days postoperatively.
In the study by Fryer et al,5 median postoperative duration of
LEV was 33 days; however, some dogs appear not to have
received any postoperative LEV, with the authors placing
emphasis on pretreatment of dogs. In the study by Brunson
et al,6 the authors similarly do not specifically report postop-
erative duration of LEV. According to pharmacokinetic data
by Moore et al,27 dogs that do not have continued administra-
tion of LEV postoperatively would be expected to have drug
plasma concentrations fall below the recommended therapeu-
tic range after approximately 12 hours. In our study, all dogs
that developed PAS in groups LEV1 and LEV2 were still
receiving LEV at the time of seizure occurrence. We
acknowledge that there is an important reliance on owners to
administer antiseizure medication at home. We defined PAS
as seizures that occurred within 7 days postoperatively, in
accordance with what has been reported in the literature.1–25
Occurrence of seizures was recorded up to 128 hours postop-
eratively in our study. It would therefore seem intuitive, when
considering prophylactically treating dogs with LEV, to con-
tinue postoperative administration for a minimum of 6 days.
In the current study, we did not exclude dogs that devel-
oped PAS that had a history of preoperative seizures. In a
recent study by Brunson et al,6 dogs with a history of preoper-
ative seizure activity that subsequently developed PAS had a
significantly increased probability of survival compared to
those that had not. It is possible that both subsets did not expe-
rience seizures of the same etiopathogenesis, although this is
purely speculative. It is also possible that some dogs that had
a history of preoperative seizures had continuation of these
seizures postoperatively. Dogs that had a history of preopera-
tive neurologic signs were also not excluded in our study.
Strickland et al7 reported that the presence of HE immediately
preoperatively was a risk factor for development of PANS
and PAS. In a study by Matushek et al,1 40% of dogs that
experienced PAS had a history of preoperative HE. We also
did not exclude dogs in which hypoglycemia, hyperammone-
mia, or electrolyte derangements were identified at the time of
PAS occurrence. Although it is possible that some dogs may
have experienced seizures directly attributable to these distur-
bances, we suspected that there would be an even distribution
of such cases across all 3 groups, which was subsequently
confirmed by statistical comparisons. None of these derange-
ments have consistently been identified within or among pre-
vious studies,1–6,8–11,15,17,21,22 nor has correction of such
abnormalities been found to abolish seizure activity in all
cases.1–4 Seizures have also been demonstrated to occur
in the face of ammonia concentrations lower than those
obtained preoperatively1,2,11 and at glucose concentrations,
albeit decreased, not typically associated with seizure activ-
ity.2,4 These clinicopathologic variables unfortunately were
not available for review for all dogs in our study, which may
have led to underestimation of the incidence of these
derangements overall and within individual PAS groups.
We acknowledge a number of important limitations in
this study. This was a retrospective study, in which accuracy
of recorded data depends on accuracy and completeness of
the medical records. Details concerning variables other than
administration of LEV were not available for all 940 dogs in
this study, and it is possible that a confounding factor may
have biased 1 or more groups toward a higher rate of PAS.
This study did not include institutions that biased administra-
tion of LEV toward dogs perceived to be at greater risk of
PAS (eg, older dogs or those that had a history of preopera-
tive neurologic signs or seizures). Therefore, the authors
speculate that a homogenous population of dogs exists over-
all within the 3 groups. Moreover, were it the case that the
LEV groups are in fact biased toward a higher proportion of
at-risk dogs, these are the dogs clinicians would be expected
to select for prophylactic treatment with LEV; however,
8.3%-11.2% of these treated dogs continued to develop PAS
in our study. Because of the nonprospective nature of this
study, administration of LEV within individual institutions
was not randomized, with the decision to pretreat with LEV
based on the attending clinician's belief regarding its possible
protective effects against development of PAS. All dogs that
developed PAS in groups LEV1 and LEV2 were still receiv-
ing LEV at the time of seizure occurrence; however, exact
timing of the last (most recent) dose relative to seizure onset
could not be verified in all cases. If this were greater than the
recommended 8-hour dosing interval, PAS may have devel-
oped due to inadequate plasma LEV concentrations rather
than a lack of efficacy of the drug. A power analysis based
on a modification of results from Fryer et al5 indicated that
284 dogs would be required in groups LEV− and LEV1 to
show a true difference in incidence of PAS if it were to exist.
Because of administration of less standardized LEV protocols
(group LEV2) within institutions in our study, a total of only
188 dogs met the inclusion criteria for group LEV1. It is pos-
sible that this shortfall may have resulted in a type II error in
our study and that a small difference does exist between
groups but could not be detected. Additional prospective ran-
domized studies are required to confirm our results. The inci-
dence of PAS in group LEV1 was almost twice that in group
LEV−, and it is possible that this is reflective of the relatively
smaller number of dogs in group LEV1. Measurement of
plasma LEV concentrations was not performed in our study
and is not routinely performed in clinical practice. We
excluded dogs that died or were euthanized within 24 hours
postoperatively for reasons unrelated to seizure activity.
This ideally would have been extended to at least 5 days;
however, several dogs were discharged prior to 5 days
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postoperatively after an uncomplicated recovery, so we could
not guarantee that they did not die of other causes within this
time frame and, thus, were not given the opportunity to
develop PAS. Because of this study's retrospective nature,
the categorization of seizure type as focal or generalized
reflects what was recorded in the medical record. Serum elec-
trolyte, ammonia, and glucose concentrations were not avail-
able for review for all dogs in this study, and this will have
affected the results of our study. Furthermore, because of this
study's multicenter nature, in cases where clinicopathologic
variables were available, these variables were obtained from
several different analyzers. Finally, we acknowledge the sub-
jectivity in assessing the degree of shunt attenuation intrao-
peratively, particularly concerning partial attenuation.
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